CalMed manufactures and distributes a range of cannulae, catheters and accessories for cardiac surgery that are currently available in 45 countries. The devices have approval from both CE Mark countries and the U.S. FDA.
The acquisitions complements Sorin’s recent grab of minimally invasive cannulae maker Estech, a deal which closed last year.
"This deal confirms Sorin Group’s commitment to further strengthen our presence in the cannulae segment and consolidate our relationship with cardiac surgeons and clinical perfusionists worldwide," Sorin Group cardiopulmonary business unit president Michel Darnaud said in prepared remarks.
Sorin has historically been a back-bencher in the U.S. device market, following behind established competitors such as Medtronic (NYSE:MDT), Boston Scientific (NYSE:BSX) and St. Jude Medical (NYSE:STJ), but the company is looking to change that.
Sorin President Stefano Di Lullo told MassDevice earlier this year that the company intends to make a run for it in America, especially with its cardiac rhythm therapy products.
Stefano’s particularly excited about the company’s SonR technology, which uses hemodynamic measurements and a software algorithm to fine-tune cardiac rhythm therapy for each patient’s particular condition.
"I really personally believe that it’s probably one of the major innovations in this space today," Di Lullo told MassDevice.com when we caught up with him at the recent Heart Rhythm Society meeting in Boston.